Brief: Imricor Medical Systems Inc Says In Fy24, Imricor Will Strategically Leverage FDA Approval For The Visabl-Afl Trial
29/02/2024 24:24
Feb 29 (Reuters) - Imricor Medical Systems Inc IMR.AX :
* IN FY24, IMRICOR WILL STRATEGICALLY LEVERAGE FDA APPROVAL
FOR
THE VISABL-AFL TRIAL
Source text for Eikon: ID:nASX9sD31s
Further company coverage: IMR.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Imricor Medical Systems
See all newsBrief: Imricor Medical Systems Says FDA Completes Review Of Imricor's Third PMA Module
Brief: Imricor Medical Systems Says FDA Accepts Imricor Pma Manufacturing Module
Brief: Imricor Medical Systems Says Anticipated FDA Clearances Of Additional Capital Equipment Expected To Broaden Product Offering Available To U.S. Customers
Imricor Medical Systems hits 3-month high on securing first US hospital customer
Brief: Imricor Medical Systems, Receives FDA 510(K) Clearance For Northstar Pediatric Label Expansion